KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.85

Patterns of Relapse After Adjuvant Chemoradiation for Cervical Cancer in a Phase 3 Clinical Trial (PARCER): An Evaluation of Updated NRG Oncology/RTOG Target Delineation Guidelines.

Prachi Mittal, Supriya Chopra, Mayuri Charnalia, Tapas Dora, Reena Engineer, Jaahid Mulani, Libin Scaria, Kunal Prajapati, Sadhana Kannan, Lavanya Gurram, Umesh Mahantshetty, Sudeep Gupta, Shyam Kishore Shrivastava

Int J Radiat Oncol Biol Phys 113(2) 369-378

PMID35157993
PMCID-
DOI10.1016/j.ijrobp.2022.02.007
发表日期2022-02-14
入排依据:The study is an original result from a phase 3 randomized trial in human cervical cancer, but it does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) with Kaplan-Meier or HR. It focuses on patterns of relapse and dose comparisons for radiation planning, not drug efficacy. The drug component (chemoradiation) is part of the trial's overall regimen, but this specific analysis is not evaluating drug intervention efficacy.
摘要

摘要

PURPOSE: The Radiation Therapy Oncology Group (RTOG) under NRG Oncology recently published updated contouring guidelines for intensity modulated radiation therapy in postoperative treatment for endometrial and cervical cancer. The present study was designed to evaluate the implications of newly published guidelines. METHODS AND MATERIALS: We recruited 300 patients in a phase 3 randomized controlled trial of adjuvant chemoradiation therapy for cervical cancer (NCT01279135) to understand patterns of relapse. For those patients with pelvic relapse, we imported radiation therapy structure sets, treatment plans, and diagnostic images at relapse on the treatment planning system. We performed rigid registration with treatment planning images that contained the delineated planning target volume and radiation dose information. We delineated gross tumor volume at time of relapse on the diagnostic scans and superimposed it on the radiation therapy treatment scans. We categorized the site of pelvic relapse as "within field of old RTOG/[Postoperative Adjuvant Radiation in Cervical Cancer (PARCER)] target delineation guidelines" or "within field of new NRG/RTOG guidelines," or both, and compared proportions of recurrences contained within the 2 guidelines. We consider a P value of <.05 statistically significant. Additionally, we generated intensity modulated radiation therapy treatment plans based on the new guidelines for a limited set of patients to see if these new guidelines increased the organ at risk doses. RESULTS: Most common form of relapse was distant metastasis (15%). Pelvic relapse rate in our study was 8%. Overall, 9 out of 19 relapses were encompassed in the contouring guidelines of the old RTOG/ Postoperative Adjuvant Radiation in Cervical Cancer (PARCER) trial, and 12 out of 19 were encompassed within the new RTOG 2021 contouring guidelines. This corresponded to a further 1% reduction in local relapses (P = .007). Dose to rectum was marginally increased with the new contouring, with no difference in other organs at risk. Salvage treatment was offered in 25 out of 60 patients who relapsed. Patients who received local treatment after relapse had a mean survival after relapse of 27.2 months compared with 8 months among those who received supportive care alone. CONCLUSIONS: Our study supports the use of newly published NRG/RTOG contouring guidelines in patients with cervical cancer who have undergone hysterectomy. Further data are needed to ascertain if anterior extension of the clinical target volume is needed as in the Postoperative Adjuvant Radiation in Cervical Cancer trial.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。